{
    "organizations": [],
    "uuid": "37f08ffcfda12905eaf530e9ae8edc751d772252",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-accepts-biologics-license-appl/brief-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-idUSASC09UMP",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Accepts Biologics License Application For Moxetumomab Pasudotox",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - AstraZeneca PLC:\n* US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMAB PASUDOTOX IN HAIRY CELL LEUKEMIA\n* FDA GRANTED MOXETUMOMAB PASUDOTOX BLA PRIORITY REVIEW STATUS WITH A PRESCRIPTION DRUG USER FEE ACT DATE SET FOR Q3 OF 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T19:07:00.000+03:00",
    "crawled": "2018-04-04T12:16:35.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "astrazeneca",
        "plc",
        "u",
        "fda",
        "accepts",
        "biologics",
        "license",
        "application",
        "moxetumomab",
        "pasudotox",
        "hairy",
        "cell",
        "leukemia",
        "fda",
        "granted",
        "moxetumomab",
        "pasudotox",
        "bla",
        "priority",
        "review",
        "status",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "date",
        "set",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}